A substantial advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and https://dawudvwmi110094.onzeblog.com/40942435/groundbreaking-approach-tirzepatide-dose-for-blood-sugar-management